Parkinsons disease - The future of invasive therapy;Die Zukunft der invasiven Parkinson-Therapie

Fortschritte der Neurologie Psychiatrie

Volumn 78, Issue SUPPL. 1, 2010, Pages

  Deuschl, G ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Deep brain stimulation; Gene therapy; Invasive therapy byParkinsons disease; Transplantation

Indexed keywords

ADENOVIRUS VECTOR; AMINO ACID DECARBOXYLASE; APOMORPHINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; GLUTAMATE DECARBOXYLASE; NEURITE PROMOTING FACTOR; NEURTURIN; PLACEBO;

BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG MECHANISM; EMBRYONIC STEM CELL; FETUS CELL; HUMAN; INVASIVE PROCEDURE; PARKINSON DISEASE; REVIEW; STEM CELL TRANSPLANTATION; VIRAL GENE THERAPY;

ANTIPARKINSON AGENTS; APOMORPHINE; DEEP BRAIN STIMULATION; GENE THERAPY; HUMANS; LEVODOPA; PARKINSON DISEASE; STEM CELL TRANSPLANTATION;

EID: 77749328879     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0029-1245168     Document Type: Review

References (36)

1. Hassler R, Mundinger F, Riechert T. Stereotaxis in Parkinson Syndrome: Clinical-anatomical contributions to its physiology, with an atlas of the basal ganglia in Parkinsonism. Berlin, Heidelberg, New York Springer Verlag 1979
2. Lindvall O, Bjorklund A. Cell therapy in Parkinsons disease. NeuroRx 2004 1 382-393
3. Bjorklund A. Intracerebral transplantation: prospects for neuronal replacement in neurodegenerative diseases. Res Publ Assoc Res Nerv Ment Dis 1993 71 361-74
4. Lindvall O, Rehncrona S, Brundin P et al. Neural transplantation in Parkinsons disease: the Swedish experience. Prog Brain Res 1990 82 729-734
5. Freed C R., Greene P E., Breeze R E. et al. Transplantation of embryonic dopamine neurons for severe Parkinsons disease. N Engl J Med 2001 344 710-719
6. Olanow C W., Goetz C G., Kordower J H. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinsons disease. Ann Neurol 2003 54 403-414
7. Kordower J H., Chu Y, Hauser R A. et al. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 2008 23 2303-2306
8. Kordower J H., Chu Y, Hauser R A. et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinsons disease. Nat Med 2008 14 504-506
9. Marks W J., Ostrem J L., Verhagen L et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinsons disease: an open-label, phase I trial. Lancet Neurol 2008 7 400-408
10. Eberling J L., Jagust W J., Christine C W. et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008 70 1980-1983
11. Kaplitt M G., Feigin A, Tang C et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinsons disease: an open label, phase I trial. Lancet 2007 369 2097-2105
12. Castaigne P, Laplane D, Dordain G. Clinical experimentation with apomorphine in Parkinsons disease. Res Commun Chem Pathol Pharmacol 1971 2 154-158
13. Stibe C M., Kempster P A., Lees A J. et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988 331 403-406
14. Poewe W, Kleedorfer B, Gerstenbrand F et al. Subcutaneous apomorphine in Parkinsons disease. Lancet 1988 1 943
15. Wenning G K., Bösch S, Luginger E et al. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinsons disease. Adv Neurol 1999 80 545-548
16. Gunzler S A., Koudelka C, Carlson N E. et al. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Arch Neurol 2008 65 193-198
17. Dewey R B., Hutton J T., LeWitt P A. et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001 58 1385-1392
18. Antonini A, Isaias I U., Canesi M et al. Duodenal levodopa infusion for advanced Parkinsons disease: 12-month treatment outcome. Mov Disord 2007 22 1145-1149
19. Nutt J G., Jansson R, Willows T et al. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005 65 1506-1507
20. Nyholm D, Nilsson Remahl A IM, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005 64 216-23
21. Weaver F M., Follett K, Stern M et al. Bilateral deep brain stimulation vs. best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. Jama 2009 301 63-73
22. Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinsons disease. N Engl J Med 2006 355 896-908
23. Deep-Brain Stimulation for Parkinsons Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinsons disease. N Engl J Med 2001 345 956-963
24. Rodriguez-Oroz M C., Obeso J A., Lang A E. et al. Bilateral deep brain stimulation in Parkinsons disease: a multicentre study with 4 years follow-up. Brain 2005 128 2240-2249
25. Okun M S., Fernandez H H., Wu S S. et al. Cognition and mood in Parkinsons disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009 65 586-595
26. Coban A, Hanagasi H A., Karamursel S et al. Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinsons disease. Br J Neurosurg 2009 23 23-29
27. Volkmann J, Allert N, Voges J et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001 56 548-551 (Pubitemid 32172887)
28. Stefani A, Lozano A M., Peppe A et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinsons disease. Brain 2007 130 1596-1607
29. Hamani C, Stone S, Laxton A et al. The pedunculopontine nucleus and movement disorders: anatomy and the role for deep brain stimulation. Parkinsonism Relat Disord 2007 13 (Suppl 3) S276-S280
30. Smith Y, Raju D, Nanda B et al. The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states. Brain Res Bull 2009 78 60-68
31. Plaha P, Gill S S. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinsons disease. Neuroreport 2005 16 1883-1887
32. Alvarez L, Macias R, Pavn N et al. Therapeutic efficacy of unilateral subthalamotomy in Parkinsons disease: results in 89 patients followed for up to 36 months. JNeurol Neurosurg Psychiatry 2009 80 979-985
33. Merello M, Tenca E, Prez Lloret S et al. Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinsons disease patients: a pilot study. Br J Neurosurg 2008 22 415-422
34. Tass P A., Silchenko A N., Hauptmann C et al. Long-lasting desynchronization in rat hippocampal slice induced by coordinated reset stimulation. Phys Rev E Stat Nonlin Soft Matter Phys 2009 80 011 902
35. Hauptmann C, Tass P A. Cumulative and after-effects of short and weak coordinated reset stimulation: a modeling study. JNeural Eng 2009 6 016 004
36. Hauptmann C, Popovych O, Tass P A. Desynchronizing the abnormally synchronized neural activity in the subthalamic nucleus: a modeling study. Expert Rev Med Devices 2007 4 633-650